A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

NCT03844256 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Urinary Bladder Cancer
Invasive Bladder Cancer

Interventions

COMBINATION_PRODUCT: nivolumab 480mg
COMBINATION_PRODUCT: nivolumab 3mg/kg, ipilimumab 1mg/kg
COMBINATION_PRODUCT: nivolumab 1mg/kg, ipilimumab 3mg/kg

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborators

[object Object]